Channing Yu
About
Channing Yu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Channing Yu has authored 30 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Channing Yu's work include Lung Cancer Treatments and Mutations (13 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer Treatment and Pharmacology (5 papers). Channing Yu is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer Treatment and Pharmacology (5 papers). Channing Yu collaborates with scholars based in United States, Japan and Taiwan. Channing Yu's co-authors include Stuart H. Orkin, Mitchell J. Weiss, Yuko Fujiwara, Jane E. Visvader, Merlin Crossley, Haidi Yang, Alan Cantor, Richard A. Wells, Daniel S. Friend and Alison A. Humbles and has published in prestigious journals such as Science, Cell and The Lancet.
In The Last Decade
Channing Yu
28 papers receiving 3.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Channing Yu United States | 17 | 1.7k | 1.0k | 906 | 805 | 499 | 30 | 3.5k | ||
| Gabriela M. Baerlocher Switzerland | 31 | 2.3k 1.3× | 2.4k 2.4× | 1.1k 1.2× | 848 1.1× | 679 1.4× | 104 | 4.8k | ||
| Dianne Sako United States | 21 | 1.4k 0.8× | 308 0.3× | 816 0.9× | 514 0.6× | 471 0.9× | 32 | 3.2k | ||
| Laure Coulombel France | 43 | 1.9k 1.1× | 555 0.5× | 1.5k 1.6× | 2.5k 3.1× | 1.1k 2.2× | 127 | 5.3k | ||
| Gerard Wagemaker Netherlands | 39 | 1.6k 1.0× | 473 0.5× | 1.1k 1.2× | 1.5k 1.9× | 465 0.9× | 146 | 4.2k | ||
| Yojiro Arinobu Japan | 26 | 781 0.5× | 550 0.5× | 1.5k 1.7× | 516 0.6× | 164 0.3× | 77 | 2.8k | ||
| Eric E. Bouhassira United States | 41 | 3.7k 2.2× | 667 0.7× | 1.4k 1.5× | 1.7k 2.1× | 1.6k 3.2× | 106 | 6.5k | ||
| Lorraine Robb Australia | 37 | 2.3k 1.3× | 323 0.3× | 1.8k 2.0× | 900 1.1× | 329 0.7× | 73 | 4.9k | ||
| K M Zsebo United States | 25 | 1.3k 0.8× | 678 0.7× | 2.3k 2.5× | 969 1.2× | 527 1.1× | 33 | 4.0k | ||
| Mitsujiro Osawa Japan | 19 | 1.8k 1.0× | 230 0.2× | 892 1.0× | 633 0.8× | 475 1.0× | 31 | 3.7k | ||
| Debra D. Pittman United States | 37 | 1.4k 0.8× | 284 0.3× | 1.2k 1.3× | 2.6k 3.3× | 1.1k 2.2× | 85 | 5.3k |
Countries citing papers authored by Channing Yu
Since
Specialization
Citations
This map shows the geographic impact of Channing Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Channing Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Channing Yu more than expected).
Fields of papers citing papers by Channing Yu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Channing Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Channing Yu. The network helps show where Channing Yu may publish in the future.
Co-authorship network of co-authors of Channing Yu
This figure shows the co-authorship network connecting the top 25 collaborators of Channing Yu. A scholar is included among the top collaborators of Channing Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Channing Yu. Channing Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jänne, Pasi A., Melissa L. Johnson, Yasushi Goto, et al.. (2021). P01.01 HERTHENA-Lung01: A Randomized Phase 2 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Previously Treated Metastatic EGFR-mutated NSCLC. Journal of Thoracic Oncology. 16(3). S236–S236.
2.
Jänne, Pasi A., Christina S. Baik, Wu‐Chou Su, et al.. (2021). Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 39(15_suppl). 9007–9007.
3.
Tripathi, Abhishek, Jeffrey G. Supko, Kathryn P. Gray, et al.. (2020). Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clinical Cancer Research. 26(23). 6122–6131.
4.
Yu, Helena A., Christina S. Baik, Kathryn A. Gold, et al.. (2020). LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC. Annals of Oncology. 31. S1189–S1190.
5.
Azeez, Kamal R. Abdul, Sneha Chatterjee, Channing Yu, et al.. (2019). Structural mechanism of synergistic activation of Aurora kinase B/C by phosphorylated INCENP. Nature Communications. 10(1). 3166–3166.
6.
Serrano, César, Adrián Mariño‐Enríquez, Derrick L. Tao, et al.. (2019). Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. British Journal of Cancer. 120(6). 612–620.
7.
Yu, Helena A., et al.. (2019). MA21.06 Preliminary Phase 1 Results of U3-1402 — A Novel HER3-Targeted Antibody–Drug Conjugate—in EGFR TKI-Resistant, EGFR-Mutant NSCLC. Journal of Thoracic Oncology. 14(10). S336–S337.
8.
Jänne, Pasi A., Helena A. Yu, Melissa L. Johnson, et al.. (2019). Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.. Journal of Clinical Oncology. 37(15_suppl). 9010–9010.
9.
Masuda, Norikazu, Kan Yonemori, Shunji Takahashi, et al.. (2019). Abstract PD1-03: Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results of a phase 1/2 trial. Cancer Research. 79(4_Supplement). PD1–3.
10.
Planchard, David, Pasi A. Jänne, Helena A. Yu, et al.. (2018). Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC. Annals of Oncology. 29. viii545–viii546.
11.
Jänne, Pasi A., et al.. (2017). P3.04-012 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination with Osimertinib in Subjects with Metastatic or Unresectable EGFR-Mutant NSCLC. Journal of Thoracic Oncology. 12(11). S2289–S2290.
12.
Kogawa, Takahiro, Kan Yonemori, Yoichi Naito, et al.. (2017). Phase 1/2, multicenter, non-randomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer.. Journal of Clinical Oncology. 35(15_suppl). TPS1116–TPS1116.
13.
Harshman, Lauren C., Kathryn P. Gray, L Polácek, et al.. (2016). An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel.. Journal of Clinical Oncology. 34(15_suppl). e16509–e16509.
14.
Li, Zhe, Frank J. Godinho, Jan‐Henning Klusmann, et al.. (2005). Developmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1. Nature Genetics. 37(6). 613–619.
15.
Yu, Channing, et al.. (1999). GATA-1 and Erythropoietin Cooperate to Promote Erythroid Cell Survival by Regulating bcl-xL Expression. Blood. 94(1). 87–96.
16.
Weiss, Mitchell J., Channing Yu, & Stuart H. Orkin. (1997). Erythroid-Cell-Specific Properties of Transcription Factor GATA-1 Revealed by Phenotypic Rescue of a Gene-Targeted Cell Line. Molecular and Cellular Biology. 17(3). 1642–1651.
17.
Visvader, Jane E., Yuko Fujiwara, Channing Yu, et al.. (1997). FOG, a Multitype Zinc Finger Protein, Acts as a Cofactor for Transcription Factor GATA-1 in Erythroid and Megakaryocytic Differentiation. Cell. 90(1). 109–119.
18.
Joung, J. Keith, et al.. (1995). Genetic strategy for analyzing specificity of dimer formation: Escherichia coli cyclic AMP receptor protein mutant altered in its dimerization specificity.. Genes & Development. 9(23). 2986–2996.
19.
Yu, Channing, Judah Folkman, R. Michael Scott, et al.. (1994). Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. The Lancet. 344(8915). 82–86.
20.
Yu, Channing. (1963). Effect of bromination on the Amino acid-accepting activities of transfer ribonucleic acids. Biochimica et Biophysica Acta (BBA) - Specialized Section on Enzymological Subjects. 76. 209–222.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Gabriela M. Baerlocher Breakdown of academic impact, for papers by Dianne Sako Breakdown of academic impact, for papers by Laure Coulombel Breakdown of academic impact, for papers by Gerard Wagemaker Breakdown of academic impact, for papers by Yojiro Arinobu Breakdown of academic impact, for papers by Eric E. Bouhassira Breakdown of academic impact, for papers by Lorraine Robb Breakdown of academic impact, for papers by K M Zsebo Breakdown of academic impact, for papers by Mitsujiro Osawa Breakdown of academic impact, for papers by Debra D. Pittman